Oppenheimer assumed coverage of Abeona Therapeutics (ABEO) with an Outperform rating and $19 price target The firm notes Abeona’s Q1 update highlighted strong early momentum following ZEVASKYN’s April approval. The first Qualified Treatment Center has been activated ahead of schedule with the first patient on track for treatment in Q3 2025. Enthusiasm from patients/caregivers and physicians remains high. Notably, management highlighted strong interest at the SID conference, Oppenheimer adds. Based on the early launch progress, the firm’s confidence in ZEVASKYN’s commercial trajectory is reaffirmed.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABEO:
- Abeona Therapeutics announces employee inducement grants
- Abeona Therapeutics Elects New Directors at Meeting
- Abeona Therapeutics: Strong Product Launch and Financial Position Justify Buy Rating
- Abeona Therapeutics Reports Improved Financial Performance
- Abeona Therapeutics’ Earnings Call Highlights ZEVASKYN Success